{"id":55815,"date":"2023-04-13T23:06:14","date_gmt":"2023-04-13T21:06:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/"},"modified":"2023-04-13T23:06:14","modified_gmt":"2023-04-13T21:06:14","slug":"veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/","title":{"rendered":"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc.<\/a> (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.<\/p>\n

<\/a><\/p>\n

\nThe conference call will be webcast live from the company\u2019s website and will be available via the following link: https:\/\/edge.media-server.com\/mmc\/p\/8zw3rvgu<\/a>. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company\u2019s website at https:\/\/investor.veracyte.com\/events-presentations<\/a>.<\/p>\n

\nThe conference call dial-ins can be accessed by registering at: https:\/\/register.vevent.com\/register\/BI87218b059133453fb9c7e07391fd40e3<\/a><\/p>\n

\nAbout Veracyte<\/b><\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/b>
Shayla Gorman – Director, Investor Relations
\n
investors@veracyte.com<\/a>
(619) 393-1545<\/p>\n

\nMedia<\/b>
Tracy Morris – Vice President of Global Corporate Communications
\n
tracy.morris@veracyte.com<\/a>
(650) 380-4413<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55815","6":"format-standard","7":"category-industry"},"yoast_head":"\nVeracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T21:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230413005769\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023\",\"datePublished\":\"2023-04-13T21:06:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/\"},\"wordCount\":331,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005769\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/\",\"name\":\"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005769\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"datePublished\":\"2023-04-13T21:06:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005769\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005769\\\/en\\\/791654\\\/21\\\/Veracyte_RGB_LRG_H_registered.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-13T21:06:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230413005769\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023","datePublished":"2023-04-13T21:06:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/"},"wordCount":331,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005769\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/","url":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/","name":"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005769\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","datePublished":"2023-04-13T21:06:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230413005769\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230413005769\/en\/791654\/21\/Veracyte_RGB_LRG_H_registered.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55815"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55815\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}